Aging
Navigate
Submit an Article
Research Paper|Volume 13, Issue 18|pp 22315—22331

High CTSL2 expression predicts poor prognosis in patients with lung adenocarcinoma

Junnian Song1, Jindong Jiang2, Na Wei1, Zongsheng Duan3, Gang Wang4, Weiyun Pan5
  • 1Department of First Operating Room, The First Hospital of Jilin University, Changchun 130021, China
  • 2Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun 130021, China
  • 3Department of Anesthesiology, The First Hospital of Jilin University, Changchun 130021, China
  • 4Department of Second Operating Room, The First Hospital of Jilin University, Changchun 130021, China
  • 5Department of Intensive Care Unit, The First Hospital of Jilin University, Changchun 130021, China
* Equal contribution
Received: April 10, 2021Accepted: September 3, 2021Published: September 23, 2021
https://doi.org/10.18632/aging.203540

Copyright: © 2021 Song et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Cathepsin like 2 (CTSL2) is a lysosomal cysteine protease, and may be associated with tumor metastasis. However, CTSL2 has not been reported as a biomarker in lung adenocarcinoma (LUAD). In this study, bioinformatics analysis using data from The Cancer Genome Atlas was performed. Wilcoxon rank-sum test and chi-square test were carried out. Kaplan-Meier and Cox regression were performed to evaluate the effect of CTSL2 expression in the overall survival. Our results indicated that CTSL2 in tumor was significantly higher than that in normal tissue (P < 0.001). High CTSL2 expression was significantly associated with age (P = 0.02), vital status (P < 0.001), and T classification (P = 0.03), and correlated with poor overall survival (HR = 1.62, 95% CI = 1.21–2.18, P = 0.001). CTSL2 expression was an independent risk factor for overall survival in patients with LUAD (HR = 1.52, 95% CI = 1.12–2.05, P = 0.006). A nomogram was plotted for illustration of CTSL2 expression on the risk of LUAD. Furthermore, in vitro cell experiments showed the CTSL2 promoted the proliferation and migration of A549 cells. In summary, high CTSL2 expression predicts poor prognosis in patients with LUAD.